Evotec SE (VIE:EVT)
Austria · Delayed Price · Currency is EUR | Market Cap | 615.72M -46.7% |
| Revenue (ttm) | 745.04M -5.5% |
| Net Income | -193.88M |
| EPS | -1.09 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 7 |
| Open | 3.490 |
| Previous Close | 3.468 |
| Day's Range | 3.490 - 3.538 |
| 52-Week Range | 3.334 - 7.246 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 13, 2026 |
About BNT
Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just – Evotec Biologics. The company is developing pharmaceutical products in various therapeutic areas, such as oncology, autoimmune, cancer, diabetes, heart failure, immunology, pain and inflammation, infectious, kidney, liver, respiratory, fibrotic and metabolic diseases, and rare diseases. It is also developingcentral nervous system (CNS) and c... [Read more]
Financial Performance
In 2025, Evotec SE's revenue was 788.37 million, a decrease of -1.08% compared to the previous year's 796.97 million. Losses were -103.52 million, -47.21% less than in 2024.
Financial StatementsNews
Evotec enters R&D collaboration with Odyssey Therapeutics
Evotec (EVO) announced that it has entered a strategic R&D collaboration with Odyssey Therapeutics (ODTX) to discover potential new treatments in autoimmune and inflammatory diseases. Under the agreem...
Evotec and Odyssey Therapeutics Enter AI-Enabled R&D Collaboration in Autoimmune and Inflammatory Diseases
Collaboration combines Odyssey's disease biology expertise with Evotec's AI-enabled discovery platform, advanced screening capabilities and proprietary compound libraries to support advancement of Ody...
Niagen Bioscience selects Evotec to advance development for NB4168
Niagen Bioscience (NAGE) announced that it has selected Evotec (EVO) as a contract research organization to support the advancement of NB4168. The work will be conducted in collaboration with NAD…
Niagen Bioscience, Inc: Niagen Bioscience Selects Global Drug Development Pioneer Evotec to Advance Preclinical Development for NB4168
Collaboration will support pharmacokinetic, pharmacodynamic, and bioanalytical studies for Niagen Bioscience's lead investigational candidate for rare pediatric diseasesEvotec brings deep drug deve...
Niagen Bioscience Selects Global Drug Development Pioneer Evotec to Advance Preclinical Development for NB4168
LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, ...
Evotec SE Slides: Company presentation
Evotec SE has posted slides in relation to its latest quarterly earnings report, which was published on August 1, 2026.
Evotec Selects Navan to Unify Global Travel, Payments, and Expense Management
PALO ALTO, Calif.--(BUSINESS WIRE)--Navan (NASDAQ: NAVN), the global AI-powered business travel and expense platform, today announced that Evotec (NASDAQ: EVO; Frankfurt Prime Standard: EVT), the glob...
Evotec price target lowered to EUR 3.50 from EUR 4.50 at Deutsche Bank
Deutsche Bank lowered the firm’s price target on Evotec (EVO) to EUR 3.50 from EUR 4.50 and keeps a Hold rating on the shares.
Evotec downgraded to Hold from Buy at Berenberg
Berenberg downgraded Evotec (EVO) to Hold from Buy with a price target of EUR 3.60, down from EUR 9.40. The company reported “disappointing” first half of 2026 results and significantly…
Evotec price target lowered to $2.40 from $3 at BofA
BofA lowered the firm’s price target on Evotec (EVO) to $2.40 from $3 and keeps an Underperform rating on the shares after the company pre-announced negative Q2 results and held…
EQS-PVR: Evotec SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
EQS Voting Rights Announcement: Evotec SE Evotec SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution 15.07.202...
Evotec price target lowered to $4 from $7 at H.C. Wainwright
H.C. Wainwright analyst Swayampakula Ramakanth lowered the firm’s price target on Evotec (EVO) to $4 from $7 and keeps a Buy rating on the shares. The firm cites the company’s…
Evotec downgraded to Hold from Buy at TD Cowen
TD Cowen downgraded Evotec (EVO) to Hold from Buy with a price target of $2, down from $4. Q2 revenue missed the firm’s and consensus estimates and management lowered FY26…
Evotec Q2 Earnings Call Highlights
Evotec NASDAQ: EVO reported preliminary unaudited results for the second quarter and first half of 2026 and lowered its full-year outlook, citing delayed strategic partnership revenue, slower conversi...
Evotec SE Earnings Call Transcript: Q2 2026
Preliminary H1 2026 results show a 19% revenue decline and negative EBITDA, driven by delayed strategic partnership revenues and continued market softness. Full-year guidance is revised downward, but strong commercial indicators and cost-saving measures support a positive long-term outlook.
Evotec SE Earnings release: Q2 2026
Evotec SE released its Q2 2026 earnings on July 14, 2026, summarizing the period's financial results.
Evotec SE Slides: Q2 2026
Evotec SE has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 14, 2026.
Ad hoc: Evotec Announces Preliminary Second Quarter and First Half 2026 Results and Updates Full-Year 2026 Outlook
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014 HAMBURG, Germany, July 13, 2026 /PRNewswire/ -- Evotec SE (NASDAQ: EVO) (Frankfurt Prime Standard: EVT) t...
Evotec Prelim Q2 & H1 2026 Results; Full-Year Outlook Updated
Evotec SE has released preliminary figures for Q2 and H1 2026, cutting its full-year outlook as revenues soften and profitability remains under pressure.
EQS-Adhoc: Ad hoc: Evotec Announces Preliminary Second Quarter and First Half 2026 Results and Updates Full-Year 2026 Outlook
EQS-Ad-hoc: Evotec SE / Key word(s): Forecast / Full year/Results / Half year Ad hoc: Evotec Announces Preliminary Second Quarter and First Half 2026 Results and Updates Full-Year 2026 Outlook 13-Jul-...
Evotec expands biologics services with J.TRAIN
Evotec (EVO) announced the expansion of its Just – Evotec Biologics services with J.TRAIN, a new offering that enables biopharmaceutical companies to deploy Evotec’s continuous manufacturing technolog...
Just - Evotec Biologics Launches J.TRAIN to Deliver Turnkey Continuous Manufacturing for Biologics
Expands Just – Evotec Biologics partner-enablement and technology licensing model for proprietary continuous manufacturing platform Enables deployment of continuous manufacturing platform in partner-o...
Evotec SE Proxy statement: Proxy filing
Evotec SE filed a proxy statement on June 23, 2026, providing details for shareholder voting and corporate governance matters.
Evotec SE Slides: Company presentation
Evotec SE has posted slides in relation to its latest quarterly earnings report, which was published on June 17, 2026.
Evotec Reports Results of the Annual General Meeting 2026
11.06.2026 / 15:30 CET/CESTThe issuer is solely responsible for the content of this announcement. All agenda items adopted Dieter Weinand and Dr. Wolfgang Hofmann newly elected to the Supervisory Boar...